TABLE 2.
Pharmacodynamic parameter estimates for unbound ISF effects of NPX in healthy and CIA rats
| Parameter | Definition | Estimate (CV%) |
|
|---|---|---|---|
| Females | Males | ||
| tonset (h) | Time of disease onset | 289 (1.07) | 308 (0.5) |
| kout (l h) | Loss of edema rate constant | 0.013 (41.3) | 0.007 (20.6) |
| kdeg (l/h) | Loss of production rate constant | 0.001 (29.0) | 0.001 (16.6) |
| kg (l/h) | Natural growth rate constant | 0.003 (33.8) | 0.002 (41.8) |
| Imax | Maximum inhibition on production of paw edema | 0.75 (40.1) | 1.0 (Fixed) |
| IC50 (µg/ml) | Unbound NPX concentration at 50% maximum inhibition | 0.221 (56.4) | 0.136 (45.9) |
| Pawss (mm2) | Paw size at steady state | 70.2 (4.6) | 102.2 (7.9) |
| kin0,c (mm2/h) | Disease production rate constant at tonset for control group | 2.21 (24.6) | 1.36 (12.0) |
| Paw0,c (mm2) | Paw size on day 0 for control group | 58.92 (1.6) | 73.49 (1.8) |
| kin0,t (mm2/h) | Disease production rate constant at tonset for treatment group | 2.31 (23.3) | 1.44 (11.6) |
| Paw0,t (mm2) | Paw size on day 0 for treatment group | 59.99 (1.6) | 76.02 (1.6) |
| Paw0,ng (mm2) | Paw size on day 0 for natural growth group | 50.38 (2.9) | 77.43 (1.8) |